Michael R. Grever

The National Cancer Institute: cancer drug discovery and development program.

Michael R. Grever, Saul A. Schepartz, B A Chabner · PubMed · 1992 · 721 citations

Medicine, Cancer Biology, Oncology +11

Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group

Bruce D. Cheson, John M. Bennett, Michael R. Grever et al. · American Journal of Hematology · 1988 · 407 citations

Medicine, Hematology, Immunology +16

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay, Susan M. Geyer, Timothy G. Call et al. · Blood · 2006 · 293 citations · Full text

Pharmacy, Immunology, Oncology +14

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

Michael R. Grever, Kenneth J. Kopecky, M K Foucar et al. · Journal of Clinical Oncology · 1995 · 268 citations

Pharmacy, Oncology, Pharmacotherapy +9

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

Janet Dancey, Kevin K. Dobbin, Susan Groshen et al. · Clinical Cancer Research · 2010 · 257 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16